•Tregs
downregulation has been implicated in the pathogenesis of many autoimmune
diseases
•Selectively
expands functional Tregs
in
vitro and
in
vivo,
and not pathogenic T effector cells (Teff)
•Restores
homeostatic balance to the immune system
•Does
not cause general immune suppression
•Current
research validates both OX40 and Notch3 as targets
•Next
plan: Determine pathway for product type (separate Notch3 and OX40 ligands, a
linked Notch3-OX40 ligand, or Notch3-OX40 bi-specific antibody) and indication
for the best regulatory path